Allianz Asset Management GmbH Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Allianz Asset Management GmbH acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,300 shares of the biotechnology company’s stock, valued at approximately $355,000.

Several other large investors also recently bought and sold shares of ARWR. State of Wyoming increased its stake in Arrowhead Pharmaceuticals by 5.6% during the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock valued at $328,000 after purchasing an additional 504 shares in the last quarter. Principal Financial Group Inc. lifted its position in Arrowhead Pharmaceuticals by 25.2% during the 3rd quarter. Principal Financial Group Inc. now owns 780,132 shares of the biotechnology company’s stock worth $26,907,000 after acquiring an additional 157,035 shares during the period. Thrivent Financial for Lutherans grew its stake in Arrowhead Pharmaceuticals by 7.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 99,744 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 7,336 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Arrowhead Pharmaceuticals by 1.9% in the third quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock valued at $1,126,000 after purchasing an additional 620 shares during the period. Finally, Summit Global Investments purchased a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth about $343,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

Insiders Place Their Bets

In other news, Director Michael S. Perry sold 16,250 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director directly owned 115,240 shares of the company’s stock, valued at $7,033,097.20. This represents a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Christopher Richard Anzalone sold 130,000 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00. Following the transaction, the chief executive officer owned 3,971,255 shares in the company, valued at $273,420,906.75. This trade represents a 3.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 510,836 shares of company stock worth $33,603,060. 3.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ARWR has been the topic of a number of recent research reports. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. Piper Sandler reissued an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Stock Up 2.3%

ARWR stock opened at $63.82 on Friday. The firm has a market cap of $8.94 billion, a PE ratio of 41.71 and a beta of 1.21. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The firm’s fifty day moving average is $67.03 and its 200 day moving average is $45.26. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same quarter last year, the company posted ($1.39) EPS. The company’s revenue was up 10461.3% on a year-over-year basis. On average, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.